In 2022, the Metagenomic Sequencing Market (メタゲノムシーケンシング市場) revenue reached US$ 1.2 Billion. The market is projected to grow at a rate of 17.6% from 2023 to 2033, potentially reaching a valuation of US$ 7.1 Billion by the end of the forecast period.
Metagenomic sequencing, a revolutionary approach in genomic analysis, has metamorphosed the landscape of microbiology, offering unparalleled insights into the vast microbial universe. This market has witnessed exponential growth, driven by its pivotal role in diverse fields, including healthcare, environmental science, agriculture, and biotechnology.
Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=Srep_id=8782
Market Dynamics
The metagenomic sequencing market is propelled by escalating demand for personalized medicine, burgeoning awareness regarding microbial diversity's significance, and technological advancements in sequencing platforms. Moreover, the plummeting costs of sequencing and robust funding for research endeavors amplify market growth. Additionally, the COVID-19 pandemic has spotlighted the importance of metagenomic sequencing in infectious disease surveillance, further fueling market expansion.
Market Future Outlook
The future of the metagenomic sequencing market (메타게놈 시퀀싱 시장) appears promising, with projections indicating sustained growth. Advancements in bioinformatics tools, coupled with enhanced sequencing technologies like nanopore sequencing and single-cell sequencing, are poised to revolutionize the market landscape. Furthermore, the integration of artificial intelligence and machine learning algorithms for data analysis promises to unlock novel insights, fostering market growth. The burgeoning applications in drug discovery, environmental monitoring, and precision agriculture are anticipated to further drive market expansion.
Market Insights
Metagenomic sequencing offers unprecedented insights into microbial communities inhabiting diverse ecosystems, from the human gut to extreme environments like hydrothermal vents. This technology enables the identification of novel microorganisms, elucidation of microbial interactions, and prediction of functional capabilities, revolutionizing our understanding of microbial ecology and evolution. Additionally, metagenomic sequencing plays a pivotal role in diagnosing infectious diseases, monitoring antimicrobial resistance, and guiding personalized treatment strategies, underscoring its clinical relevance.
Key Players
- Illumina, Inc.
- Thermo Fisher Scientific
- QIAGEN
- PerkinElmer, Inc.
- Oxford Nanopore Technologies Plc.
- Pacific Biosciences of California, Inc.
- BGI Group
- Psamogen, Inc.
- Eurofins Scientific
- Azenta Life Sciences
- Novogen Co. Ltd.
- Zymo Research Corporation
- Tecan Trading AG
- Integragen SA
- Microsynth AG
Competitive Landscape
In July 2021, Pacific Biosciences and Invitae, a leading medical genetics company, announced a partnership. This collaboration aims to combine PacBio's long-read sequencing technology with Invitae's expertise in clinical genetic testing, creating a high-throughput sequencing platform for genetic testing.
In February 2021, Thermo Fisher partnered with Janssen Pharmaceuticals, a subsidiary of Johnson Johnson, to develop a companion diagnostic test for a cancer drug. The test will utilize Thermo Fisher's NGS technology to identify patients likely to respond to the drug.
In December 2020, Illumina acquired Pacific Biosciences for approximately US$ 1.2 billion. This acquisition is expected to leverage the strengths of both companies in the field of DNA sequencing.
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RCrep_id=8782
Segmentation of the Metagenomic Sequencing Market (Marché du séquençage métagénomique):
- By Product Service :
- Reagents Consumables
- Instruments
- Services
- Analysis Data Interpretation Solutions
- By Workflow :
- Sample Processing Library Preparation
- Sequencing
- Data Processing Analysis
- By Technology :
- Shotgun Metagenomic Sequencing
- 16S rRNA Sequencing
- Metatranscriptomics
- Whole-genome Sequencing De Novo Assembly
- By Application :
- Drug Discovery
- Clinical Diagnostics
- Soil Microbiome Application
- Industrial Applications
- Ecology and Environmental Applications
- Veterinary Applications
- Other Applications
- By Region :
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East Africa
About Fact.MR :
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400 Rockville, MD 20852
United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: [email protected]
